Eloxx Pharmaceuticals (NASDAQ:ELOX) & Coeptis Therapeutics (NASDAQ:COEP) Financial Comparison

Coeptis Therapeutics (NASDAQ:COEP) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by insiders. Comparatively, 20.2% of Eloxx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Coeptis Therapeutics and Eloxx Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	0	1	0	0	2.00
Eloxx Pharmaceuticals	0	0	0	0	0.00

Given Eloxx Pharmaceuticals’ higher possible upside, analysts plainly believe Eloxx Pharmaceuticals is more favorable than Coeptis Therapeutics.

Valuation & Earnings

This table compares Coeptis Therapeutics and Eloxx Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$80,000.00	147.00	-$21.27 million	($5.80)	-0.99
Eloxx Pharmaceuticals	N/A	N/A	-$36.06 million	($9.07)	N/A

Coeptis Therapeutics has higher revenue and earnings than Eloxx Pharmaceuticals. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Coeptis Therapeutics has a beta of -1.04, meaning that its stock price is 204% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of 2.49, meaning that its stock price is 149% more volatile than the S&P 500.

Profitability

This table compares Coeptis Therapeutics and Eloxx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	N/A	-1,094.50%	-219.97%
Eloxx Pharmaceuticals	N/A	N/A	N/A

Summary

Coeptis Therapeutics beats Eloxx Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.